Immunotherapy at different times of day for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy at different times of the day (chrono-immunotherapy) is better for people with advanced melanoma. It looks at how timing might affect how well the treatment works and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or stage IV melanoma that cannot be removed with surgery.
- You have not had prior systemic treatment for melanoma, or if you had adjuvant therapy, it was more than 6 months ago.
- You are 18 years or older and can manage your daily activities (ECOG 0-2).
- If you have brain metastases, you can still join.
- You are willing to use effective birth control during the study and for 5 months after the last dose.
- You have not had an organ transplant and are not allergic to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.